← Back to Clinical Trials
Recruiting NCT05558605

NCT05558605 Use of Artificial Intelligence-Guided Echocardiography to assIst cardiovascuLar Patient managEment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05558605
Status Recruiting
Phase
Sponsor Baker Heart and Diabetes Institute
Condition Heart Failure
Study Type INTERVENTIONAL
Enrollment 612 participants
Start Date 2023-02-24
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 45 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
AI-guided echoStandard echo

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 612 participants in total. It began in 2023-02-24 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Heart Failure and valvular heart disease are disproportionate problems in rural and remote Australia (RRA). Echocardiography is the best imaging investigation, and essential for management, but access to this essential test shows huge geographic variations, primarily because of dependence on expert acquisition. This trial seeks to demonstrate the effectiveness of artificial intelligence-based echocardiography for triage and management of patients with known or suspected heart disease in RRA.

Eligibility Criteria

Inclusion Criteria: * Age \>45 years * eligible for Medicare * exercise intolerance or cardiovascular (CV) risk factors Exclusion Criteria: * Known HF or HVD * situations where cardio-protection is already indicated (eg. known CAD) * comorbid conditions with life expectancy \<2 years * inability to provide written informed consent

Contact & Investigator

Central Contact

Tom Marwick, MBBS, PhD

✉ tom.marwick@baker.edu.au

📞 +61385321550

Principal Investigator

Tom Marwick, MBBS, PhD

PRINCIPAL INVESTIGATOR

Baker Heart and Diabetes Institute

Frequently Asked Questions

Who can join the NCT05558605 clinical trial?

This trial is open to participants of all sexes, aged 45 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05558605 currently recruiting?

Yes, NCT05558605 is actively recruiting participants. Contact the research team at tom.marwick@baker.edu.au for enrollment information.

Where is the NCT05558605 trial being conducted?

This trial is being conducted at Alice Springs, Australia.

Who is sponsoring the NCT05558605 clinical trial?

NCT05558605 is sponsored by Baker Heart and Diabetes Institute. The principal investigator is Tom Marwick, MBBS, PhD at Baker Heart and Diabetes Institute. The trial plans to enroll 612 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology